DF
HZNP

Donoghue Forlines’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Donoghue Forlines’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,260
Closed -$264K – 280
2022
Q3 		$264K Sell
4,260
-4,284
-50% -$299K 0.1% 186
2022
Q2 		$681K Buy
+8,544
New +$809K 0.18% 141

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Donoghue Forlines's HZNP Position: Q4 2022 in Review

Donoghue Forlines sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 4,260 shares — an estimated $264K sold.

Donoghue Forlines first reported a position in HZNP in Q2 2022 and held it in 2 quarters. The position peaked at $681K in Q2 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

  • Donoghue Forlines reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Donoghue Forlines sold 4,260 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $264K.
  • Donoghue Forlines first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 2 quarters.
  • Donoghue Forlines's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $681K in Q2 2022.
  • 615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Donoghue Forlines's 13F filing for Q4 2022, filed 8 Feb 2023.